Related Experiment Video

Updated: Jul 15, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Case-control study of perinatal factors and hepatoblastoma in children with an extremely low birthweight

K Maruyama1, H Ikeda, T Koizumi

  • 1Department of Neonatology, Gunma Children's Medical Center, Seta-gun, Japan. maruken@gcmc.pref.gunma.jp

Pediatrics International : Official Journal of the Japan Pediatric Society
|November 4, 2000
PubMed

Insights

Oxygen therapy and furosemide treatment are significant risk factors for hepatoblastoma in extremely low birthweight infants. Longer oxygen therapy duration is the most critical predictor for developing this childhood cancer.

Area of Science:

  • Pediatric Oncology
  • Neonatology
  • Cancer Risk Factors

Background:

  • Hepatoblastoma shows a notable association with low birthweight.
  • This case-control study investigated risk factors for hepatoblastoma in extremely low birthweight infants (< 1,000 g).

Purpose of the Study:

  • To identify risk factors for hepatoblastoma in extremely low birthweight infants.
  • To determine the most significant predictor for hepatoblastoma development in this vulnerable population.

Main Methods:

  • A case-control study comparing 12 hepatoblastoma cases with 75 matched controls.
  • Analysis of prenatal and postnatal histories, including parental data.
  • Utilized univariate and multivariate Cox regression analyses.

Main Results:

  • Infants with hepatoblastoma had lower gestational age and longer time to regain birthweight.
  • Significantly longer durations of oxygen therapy and furosemide treatment were observed in hepatoblastoma cases.
  • Multivariate analysis identified the duration of oxygen therapy as an independent risk factor (HR = 1.006, P = 0.001).

Conclusions:

  • Oxygen therapy, furosemide treatment, and growth rate are risk factors for hepatoblastoma in extremely low birthweight infants.
  • The duration of oxygen therapy is the primary predictor for hepatoblastoma development.
  • Further research is needed to elucidate underlying causes and develop preventative strategies.
Abstract

More Related Videos

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 105:44

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1

Published on: May 17, 2024

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...